NCT01572012View on ClinicalTrials.gov

Phase 1 Safety, Tolerability and PK Study of Ondansetron and Hylenex Recombinant in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

November 30, 2013

Study Completion Date

November 30, 2013

Conditions
Healthy
Interventions
DRUG

Ondansetron

Ondansetron solution 4 mg single administration

DRUG

Ondansetron + Hylenex

Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration

DRUG

Zofran ODT

Zofran ODT (8 mg) single administration

DRUG

Ondansetron solution

Ondansetron solution (4 mg) single administration

Trial Locations (1)

78209

Icon Development Solutions, San Antonio

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY